Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology Vol. 18; no. 1; pp. 28 - 4
Main Authors: Bu, Qiling, Zhu, Hong-Hu, Chen, Wenming
Format: Journal Article
Language:English
Published: London BioMed Central 07.03.2025
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Amyloid
Amyloidosis
Antigens
Cancer Research
Clinical trials
Conferences, meetings and seminars
Correspondence
Drug dosages
Hematology
Humans
Immunoglobulin light chain amyloidosis
Immunoglobulin Light Chains - metabolism
Immunoglobulin Light-chain Amyloidosis - drug therapy
Immunoglobulin Light-chain Amyloidosis - therapy
Immunoglobulins
Latest updates from major conferences
Light
Light chains
Medicine
Medicine & Public Health
Molecular Targeted Therapy - methods
Monoclonal antibodies
Multiple myeloma
Oncology
Peptides
Plasma cells
Remission
Response rates
Targeted therapies
Targeted therapies
Clinical trials
Immunoglobulin light chain amyloidosis
ISSN:1756-8722, 1756-8722
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Correspondence-4
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-025-01681-7